text: Jemma Peacock (pictured on her wedding day) says the NHS is denying her two daughters (pictured) their mother by refusing to fund a life-saving drug . A terminally-ill cancer sufferer has accused the NHS of denying her two daughters their mother by refusing to fund a potentially life-extending drug. Jemma Peacock, 31, suffers from a rare form of stomach cancer and is currently taking three drugs to try to prolong her life. The third and most effective drug - regorafenib - costs the NHS around £1,000 a week to provide and has been removed from the health service's approved list of treatments. Mrs Peacock, who lives with her husband Tony and daughters Kacie, six, and Willow, four, in Storrington, West Sussex, has wild-type gastrointestinal cancer, which causes tumours to grow in the stomach and intestines. The mother-of-two, who is yet to tell her young children about her condition, says she cannot afford to buy regorafenib privately and has called on NHS England to reverse their decision. She said: 'The final drug is the most effective and it is heart breaking they have removed it from the treatment list. 'The cancer that I have is extremely rare and the research into it is limited so it angers me that they are removing a drug that has been proven to work. 'I am lucky that I have managed to spend 14 months on the first drug, Imatinib, in the series but I know that it will soon have no effect on my body. 'The second drug, Sutan, is not very effective and I know that when I have to be put on it I will have minimal time left. 'You can buy regorafenib privately but that costs £3,700 a month and I don't have that kind of money. 'Family members have offered to sell their houses and belongings to pay for my treatment but I can't accept that. 'I cannot ask my family to put their lives on hold when I might only get another year of life.' Mrs Peacock (pictured with daughters Kacie, left, and Willow, right), who has a rare form of stomach cancer, has been refused a drug which could help her battle the disease . The mother-of-two, who set up a 100,000-strong petition for the drug regorafenib to be funded, has not told her daughters that she has cancer . Mrs Peackock, who lives in Storrington, West Sussex, with her daughters and husband Tony, has wild-type gastrointestinal cancer, which causes tumours to grow in the stomach and intestines . After NHS England removed the drug from their list of treatments in January this year, Mrs Peacock launched a petition calling on the NHS to reinstate it. More than 100,000 people have signed it, meaning MPs will have to discuss the issue in Parliament when they return to the Commons after the election - but by then Mrs Peacock's cancer may have progressed. Despite thousands joining her cause, Mrs Peacock is yet to tell her daughters that she has cancer. 'I do not want to scare them with what I am going through,' she said. 'We had to watch my dad die of lung cancer just 18 months ago and the girls found that really tough as they were very close to him. 'If I told them I had cancer it would scare them and no parent wants to scare their child. I do spoil them more then what other parents would but who can blame me. 'I want them to have as many happy memories with us as a family as possible before I get too ill and I can no longer enjoy the time I have. 'I think about the conversation I will have to have with them in the future and it heart wrenching that I will have to tell my daughters I will soon not be here anymore. 'But I know that I have to push that conversation to the back of mind and enjoy the time I have left with my family.' The NHS currently spends in the region of £1.3billion on cancer drugs a year, and receives a further £200million annual boost from the Cancer Drugs Fund - which helps to fund treatments for rare forms of the disease. NHS England then decides what drugs this money goes towards, with a ruling in January removing regorafenib from the fund's list because the treatment's effectiveness did not represent 'sufficient value for retention'. The report found that, on average, it cost £4,493 to provide a four-week cycle of regorafenib to a patient, with the average recipient needing the drug for 23 weeks. NHS England declined to comment.
target: Mother-of-two Jemma Peacock, 31, has a rare form of stomach cancer .
  NHS England has refused funding for a drug which could prolong her life .
  Mrs Peacock accused health service of denying her daughters their mother .
  Drug would cost the NHS £1,000 a week to provide and mother cannot afford to pay for it privately .